2021 Fiscal Year Research-status Report
Light-activatable nanoparticles to treat triple negative breast cancers
| Project/Area Number |
21K14508
|
|---|
| Research Institution | National Institute of Advanced Industrial Science and Technology |
|---|
Principal Investigator |
于 躍 国立研究開発法人産業技術総合研究所, 生命工学領域, 研究員 (90881631)
|
|---|
| Project Period (FY) |
2021-04-01 – 2023-03-31
|
| Keywords | cancer / nanomedicine / phototherapy / cell signaling |
|---|
| Outline of Annual Research Achievements |
Triple-negative breast cancer (TNBC) is an aggressive disease that grows quickly and metastasizes early. There are no effective therapies for TNBC, so new strategies are needed. The goal of this project is to meet this need using functional nanoparticles that can optically control TNBC-associated signaling transductions on demand. Success in this therapy not only will improve survival and quality of life for patients with TNBC, but may also be expanded to other stubborn diseases with different light-sensitive molecular drivers.
In FY2021, the following achievements have been made.
(1) We have successfully fabricated a light-responsive nanocomplex that can be well dispersed in the water.
(2) The newly synthesized nanocomplex has excellent photothermal conversion efficiency in responsive to tissue-penetrating near infrared light irradiation and shows low toxicity to human normal cells,
(3) We have modified the nanocomplexes with TNBC targeting molecules, so that they can selectively accumulate to TNBC cells.
(4) Preliminary biomolecular analysis indicates that incubation of light-driven nanocomplexes with TNBC cells down-regulates the expressions of proteins associated to tumor progression.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
According to the original research schedule, the targeted functional nanoparticles are successfully generated for TNBC phototherapy. Some preliminary results of in vitro experiments are also obtained for the preparation of studies in FY2022.
|
| Strategy for Future Research Activity |
In FY2022, we will focus on the biological effects of the light-responsive nanocomplexes, such as their impacts on TNBC growth and metastasis. The involved mechanisms in the context of cellular signaling will be also studied using TNBC cells after the nanocomplex treatment.
|
| Causes of Carryover |
This small amount of budget will be used for purchasing chemicals in the fiscal year.
|
